文献速递产科麻醉疼痛医学

腹腔内滴注利多卡因改善剖宫产术后镇痛:随机双盲安慰剂对照试验

Intraperitoneal Instillation of Lidocaine Improves Postoperative Analgesia at Cesarean Delivery: A Randomized, Double-Blind, Placebo-Controlled Trial.
PubMed 文献 · Anesth Analg · 2017-01-01

主要结局24小时活动痛无差异,但利多卡因组2小时活动痛和静息痛更低,术后请求阿片类药物比例显著降低(40% vs 65%)。

要点

  • 腹腔内滴注利多卡因可改善剖宫产术后早期(2小时)疼痛评分。
  • 利多卡因组术后请求阿片类药物比例显著低于安慰剂组(40% vs 65%)。
  • 腹膜关闭亚组中利多卡因组24小时活动痛显著更低。

核心结论

  • 腹腔内滴注利多卡因改善剖宫产术后早期镇痛,并减少产后即刻系统阿片类药物需求。
  • 腹膜关闭的产妇可能尤其受益于该干预。

研究设计与样本

  • 脊麻使用0.75%重比重布比卡因、芬太尼和吗啡。
  • 关腹前随机腹腔内滴注2%利多卡因20mL(含肾上腺素)或生理盐水20mL。
  • 主要结局为24小时活动痛评分。

主要发现

  • 2小时活动痛(参数估计-0.58,95%CI -0.90至-0.26,P=0.001)和静息痛(参数估计-1.00,95%CI -1.57至-0.43,P=0.001)利多卡因组更低。
  • 请求术后阿片类药物的产妇比例利多卡因组40%(40例) vs 安慰剂组65%(61例),相对风险0.59(95%CI 0.43-0.81),P=0.001。

临床怎么用

  • 剖宫产关腹前可考虑腹腔内滴注2%利多卡因20mL(含肾上腺素)作为多模式镇痛的一部分。
  • 该干预可能减少术后早期阿片类药物需求,尤其对腹膜关闭者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cesarean delivery is a commonly performed procedure worldwide. Despite improvements in balanced multimodal analgesia, there remains a proportion of women for whom postoperative pain relief and patient satisfaction are still inadequate. Intraperitoneal instillation of local anesthetic has been shown to be effective in reducing postoperative pain after abdominal surgery. We sought to investigate the effect of intraperitoneal instillation of lidocaine on postcesarean delivery pain as part of a multimodal analgesia regimen. METHODS: We studied women scheduled for elective cesarean delivery under spinal anesthesia. Spinal anesthesia was performed with 0.75% hyperbaric bupivacaine, fentanyl, and morphine. At the end of the cesarean delivery, immediately before parietal peritoneum or fascia closure, patients were randomized to receive either lidocaine (20 mL 2% lidocaine with epinephrine) or placebo (20 mL normal saline) instilled into the peritoneal cavity. The primary outcome was pain score on movement at 24 hours. Secondary outcomes were pain score at rest and on movement at 2, 24, and 48 hours; maternal satisfaction score; analgesic consumption; incidence of nausea, vomiting, and itching; and return of bowel function. RESULTS: Two hundred four women were recruited. Baseline characteristics were similar between the lidocaine and placebo groups. Pain scores at 24 hours postcesarean delivery on movement (parameter estimate 0.02 [95% confidence interval {CI} -0.14 to 0.18]; P = .823) and at rest (parameter estimate 0.00 [95% CI -0.32 to 0.33]; P = .986) were similar in both groups. Pain scores at 2 hours postcesarean delivery on movement (parameter estimate -0.58 [95% CI -0.90 to -0.26]; P = .001) and at rest (parameter estimate -1.00 [95% CI -1.57 to -0.43]; P = .001) were lower in the lidocaine group. Subgroup analysis of patients with peritoneum closure revealed significantly lower pain scores at 24 hours on movement (parameter estimate -0.33 [95% CI -0.64 to -0.03]; P = .032) in the lidocaine group. The number of women requesting postoperative opioids for breakthrough pain was significantly lower in the lidocaine group compared with that of the placebo (40 [40%] vs 61 [65%], respectively, relative risk 0.59 [95% CI 0.43-0.81]; P = 0.001). CONCLUSIONS: The use of intraperitoneal instillation of lidocaine improves early postoperative pain management after cesarean delivery. Furthermore, it reduces the number of women requesting systemic opioids in the immediate postpartum period. Women undergoing peritoneal closure may particularly benefit from this intervention.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Patel R, Carvalho JC, Downey K, et al. Intraperitoneal Instillation of Lidocaine Improves Postoperative Analgesia at Cesarean Delivery: A Randomized, Double-Blind, Placebo-Controlled Trial. Anesth Analg. 2017. PMID: 27984226. doi:10.1213/ANE.0000000000001799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。